within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC05_Ustekinumab;

model Ustekinumab
  extends Pharmacolibrary.Drugs.ATC.L.L04AC05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L04AC05</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ustekinumab is a human monoclonal antibody targeting interleukin-12 (IL-12) and interleukin-23 (IL-23), used primarily for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is approved for clinical use in many countries and is considered a biologic therapy for immune-mediated inflammatory disorders.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters for ustekinumab in adults with moderate to severe plaque psoriasis after subcutaneous administration.</p><h4>References</h4><ol><li><p>Grabowski, T, et al., &amp; Borkowski, J (2021). Ustekinumab pharmacokinetics after subcutaneous administration in swine model. <i>Journal of veterinary science</i> 22(5) e47–None. DOI:<a href=&quot;https://doi.org/10.4142/jvs.2021.22.e47&quot;>10.4142/jvs.2021.22.e47</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34423596/&quot;>https://pubmed.ncbi.nlm.nih.gov/34423596</a></p></li><li><p>Feagan, BG, et al., &amp; Rutgeerts, P (2016). Ustekinumab as Induction and Maintenance Therapy for Crohn&#x27;s Disease. <i>The New England journal of medicine</i> 375(20) 1946–1960. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa1602773&quot;>10.1056/NEJMoa1602773</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27959607/&quot;>https://pubmed.ncbi.nlm.nih.gov/27959607</a></p></li><li><p>Weber, J, &amp; Keam, SJ (2009). Ustekinumab. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 23(1) 53–61. DOI:<a href=&quot;https://doi.org/10.2165/00063030-200923010-00006&quot;>10.2165/00063030-200923010-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19344192/&quot;>https://pubmed.ncbi.nlm.nih.gov/19344192</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Ustekinumab;
